An Anti-CGRP Antibody Expands the Pediatric Migraine Toolbox: A Look at the Data - Migraine Science Collaborative A recent randomized, controlled trial testing fremanezumab in children and adolescents with episodic migraine showed a reduction in monthly migraine days.

MSC News: A recent randomized controlled trial testing #fremanezumab in children and adolescents with episodic #migraine showed a reduction in monthly migraine days.

migrainecollaborative.org/an-anti-cgrp...

¿Un fármaco por fin frena la migraña infantil? Vall d’Hebron El ensayo SPACE con Vall d’Hebron confirma que fremanezumab reduce días de migraña en niños y adolescentes y abre una nueva etapa preventiva. La migraña en niños y adolescentes acaba de sumar una evid...

¿Un fármaco por fin frena la migraña infantil? Vall d’Hebron #migraña #saludinfantil #neurologia #pediatria #ValldHebron #Barcelona #CGRP #fremanezumab #ensayoclinico #medicina #saludmental #dolordecabeza #25defebrero #felizmiercoles #ciencia donporque.com/farmaco-por-...

Fremanezumab may prevent episodic migraines in children and adolescents 3 months of fremanezumab treatment significantly reduced monthly migraine and headache days in children and adolescents with episodic migraine relative to placebo.

#MedNews - 3 months of #fremanezumab treatment significantly reduced monthly #migraine and #headache days in children and adolescents with episodic migraine relative to placebo.

Full story 👉 buff.ly/yZv9553

#NeuroSky

FDA Approves Expanded Indication for AJOVY® (fremanezumab-vfrm), The First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine FDA approves single-dose AJOVY ® (fremanezumab-vfrm) injection for the preventive treatment of episodic migraine in children and adolescents aged 6-17 who weigh 45 kilograms or more, offering a long-a...

FDA has approved #fremanezumab for #migraine #prevention in #children and #adolescents with #episodic #migraine ir.tevapharm.com/news-and-eve...

Excellent work by @fredakreier.bsky.social

Check out her latest story for @migrainecollab.bsky.social, which covers a recent clinical trial of an anti-CGRP antibody to treat both migraine AND comorbid depression. #headache #migraine #fremanezumab

Migräne plus Depression: Fremanezumab wirkt doppelt Migräne und schwere Depression treten häufig gemeinsam auf. Der monoklonale CGRP-Antikörper Fremanezumab hat in einer Studie gezeigt, dass sich mit ihm beide Komorbiditäten gleichzeitig lindern lassen.

Migräne und schwere #Depression treten häufig gemeinsam auf. Der monoklonale CGRP-Antikörper #Fremanezumab hat in einer Studie gezeigt, dass sich mit ihm beide Komorbiditäten gleichzeitig lindern lassen. #medsky #Medizin #Migräne

Fremanezumab for the Treatment of Patients With Migraine and Comorbid Major Depressive Disorder This randomized clinical trial investigates if treatment with fremanezumab compared with placebo leads to improvements in migraine and depressive symptoms in patients with migraine and comorbid major ...

Fascinating results from UNITE trial showing that #fremanezumab reduces both #migraine days and #depressive symptoms in adults with #migraine and #depression - seminal trial first to look at treating both @jama.com: jamanetwork.com/journals/jam...

Anti-CGRP Drug Reduces Episodic Migraine in Kids Fremanezumab shows safety, efficacy in phase III trial of pediatric patients

"For the first time, there's a CGRP-targeting treatment that has demonstrated statistical and clinically meaningful results in children as young as the age of 6." -- Hope O'Brien, MD, MBA, on a trial of #fremanezumab (Ajovy) in children and adolescents. #AAN2025
www.medpagetoday.com/meetingcover...

Teva's Ajovy shows positive results in preventing pediatric migraines - PharmaTimes Phase 3 trial indicates significant efficacy and safety for children and adolescents

#neurology #migraine #Teva #TevaPharmaceuticals #Ajovy #fremanezumab #paediatricmigraines #paediatricmigraineprevention #Phase3SPACEstudy #episodicmigraines #episodicmigraineprevention #chronicmigraine #migraine #SPACEtrial #paediatricpatients #CGRPpathwaytreatment
pharmatimes.com/news/tevas-a...